Serum periplakin as a potential biomarker for urothelial carcinoma of the urinary bladder

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 22, 2014, Pages 9927-9931

  Matsumoto, Kazumasa ^a   Ikeda, Masaomi ^a   Matsumoto, Toshihide ^a   Nagashio, Ryo ^a   Nishimori, Takanori ^b   Tomonaga, Takeshi ^c   Nomura, Fumio ^b   Sato, Yuichi ^a   Kitasato, Hidero ^a   Iwamura, Masatsugu ^a  

^a KITASATO UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

Diagnosis; Periplakin; Urothelial carcinoma

Indexed keywords

PLAKIN; PPL PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; BLADDER; BLOOD; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; CYSTOSCOPY; CYTODIAGNOSIS; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MUSCLE NEOPLASMS; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR INVASION; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CYSTOSCOPY; CYTODIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MUSCLE NEOPLASMS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PLAKINS; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84921498092     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.22.9927     Document Type: Article

References (27)

1. Chao Y, Shih YL, Chiu JH, et al (1998). Overexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma. Cancer Res, 58, 985-90.
2. Choi YK, Woo SM, Cho SG, et al (2013). Brain-metastatic triple-negative breast cancer cells regain growth ability by altering gene expression patterns. Cancer Genomics Proteomics, 10, 265-75.
3. Clark AS, West K, Streicher S, Dennis PA (2002). Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther, 1, 707-17.
4. Dobashi Y, Shoji M, Jiang SX, et al (1998). Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am J Pathol, 153, 963-72.
5. Gagnon V, Mathieu I, Sexton E, et al (2004). AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol, 94, 785-95.
6. Ghafouri-Fard S, Nekoohesh L, Motevaseli E (2014). Bladder cancer biomarkers: review and update. Asian Pac J Cancer Prev, 15, 2395-403.
7. Hatakeyama H, Kondo T, Fujii K, et al (2006). Protein clusters associated with carcinogenesis, histological differentiation and nodal metastasis in esophageal cancer. Proteomics, 6, 6300-16.
8. Ikeda M, Matsumoto K, Nishi M, et al (2014). Comparison of radical cystectomy and chemoradiotherapy in patients with locally advanced bladder cancer. Asian Pac J Cancer Prev, 15, 6519-24.
9. Ikeda M, Matsumoto K, Tabata K, et al (2011). Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy. Jpn J Clin Oncol, 41, 1214-20.
10. Jefferson JJ, Leung CL, Liem RK (2004). Plakins: goliaths that link cell junctions and the cytoskeleton. Nat Rev Mol Cell Biol, 5, 542-53.
11. Matsumoto K, Ikeda M, Hirayama T, et al (2014). Clinical value of dividing false positive urine cytology findings into three categories: atypical, indeterminate, and suspicious of malignancy. Asian Pac J Cancer Prev, 15, 2251-5.
12. Matsumoto K, Ikeda M, Sato Y, et al (2014). Loss of periplakin expression is associated with pathological stage and cancer-specific survival in patients with urothelial carcinoma of the urinary bladder. Biomed Res, 35, 201-6.
13. Minami S, Nagashio R, Ueda J, et al (2014). Detection of tumor-associated antigens in culture supernatants using autoantibodies in sera from patients with bladder cancer. Biomed Res, 35, 25-35.
14. Mrena J, Wiksten JP, Kokkola A, et al (2006). Prognostic significance of cyclin A in gastric cancer. Int J Cancer, 119, 1897-901.
15. Nagata Y, Karashima T, Watt FM, et al (2001). Paraneoplastic pemphigus sera react strongly with multiple epitopes on the various regions of envoplakin and periplakin, except for the c-terminal homologous domain of periplakin. J Invest Dermatol, 116, 556-63.
16. Nishimori T, Tomonaga T, Matsushita K, et al (2006). Proteomic analysis of primary esophageal squamous cell carcinoma reveals downregulation of a cell adhesion protein, periplakin. Proteomics, 6, 1011-8.
17. Park GT, Quan G, Lee JB (2006). Sera from patients with toxic epidermal necrolysis contain autoantibodies to periplakin. Br J Dermatol, 155, 337-43.
18. Shelley MD, Mason MD, Kynaston H (2010). Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat Rev, 36, 195-205.
19. Sonnenberg A, Liem RK (2007). Plakins in development and disease. Exp Cell Res, 313, 2189-203.
20. Sun CH, Chang YH, Pan CC (2011). Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology, 58, 1054-63.
21. Suzuki A, Horiuchi A, Ashida T, et al (2010). Cyclin A2 confers cisplatin resistance to endometrial carcinoma cells via up-regulation of an Akt-binding protein, periplakin. J Cell Mol Med, 14, 2305-17.
22. Taille C, Grootenboer-Mignot S, Boursier C, et al (2011). Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 183, 759-66.
23. Toma MI, Friedrich MG, Hautmann SH, et al (2004). Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World J Urol, 22, 145-9.
24. Tonoike Y, Matsushita K, Tomonaga T, et al (2011). Adhesion molecule periplakin is involved in cellular movement and attachment in pharyngeal squamous cancer cells. BMC Cell Biol, 12, 41.
25. Tsumura H, Matsumoto K, Matsumoto T, et al (2014). Increased expression of serum uroplakin III is associated with the detection and pathological features of aggressive bladder cancer. Eur Urol Suppl, 13, 48.
26. van den Heuvel AP, de Vries-Smits AM, van Weeren PC, et al (2002). Binding of protein kinase B to the plakin family member periplakin. J Cell Sci, 115, 3957-66.
27. Yang X, Fraser M, Moll UM, et al (2006). Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res, 66, 3126-36.